UBS Downgrades GE HealthCare to Sell Amid Competitive Pressures
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 Jan 26
Source: Investing.com
GE HealthCare Technologies Inc. is experiencing a decline of 3.38% as it hits a 20-day low, reflecting broader market challenges. UBS has downgraded the company's rating from Neutral to Sell, citing that the current valuation does not adequately reflect the risks posed by increased competition, particularly from Chinese firms. This downgrade comes despite the company's previous strong performance, driven by investor enthusiasm over its tariff mitigation efforts and the new Flyrcado product, which are now overshadowed by concerns about future earnings growth and competitive pressures in the market.
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is 92.25 USD with a low forecast of 80.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 78.780
Low
80.00
Averages
92.25
High
105.00
Current: 78.780
Low
80.00
Averages
92.25
High
105.00
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
